In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy Fights To Convince Sales Staff No Changes With Daiichi Buy

This article was originally published in PharmAsia News

Executive Summary

Even as Japan's Daiichi Sankyo's bid to buy India's Ranbaxy Laboratories neared completion, sales personnel, some of them with the company for more than two decades, face a new way in doing business. Ranbaxy's sales force numbers about 2,000, but as part of Daiichi it now is representing the world's 15th largest drug maker. The head of that force, Vivek Sawant, says physicians at first had a hard time believing the Ranbaxy operation would remain unchanged by the merger. Some doctors, and the medical representatives who deal with them, had problems with the idea of losing a local company to a foreign owner, but thanks to a strong effort, Ranbaxy believes it has convinced physicians its products and service would remain unchanged. (Click here for more



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts